- active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy after surgery for certain types of womb cancer (endometrial cancer). We want to see if this combination helps stop the cancer from coming back and helps people live longer compared to chemotherapy alone.
United States · Argentina · Austria - recruitingPHASE1
A Study of LY4175408 in Participants With Advanced Cancer
This study is looking at a new medicine called LY4175408 for people with certain advanced cancers, including lung, womb, and a type of breast cancer. It aims to see if the medicine is safe, how well it works, and how the body handles it.
United States · China · France - recruitingPHASE2
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
This study looks at new treatments (Dostarlimab alone or with Bevacizumab) for certain gynaecological cancers that have come back or not responded to previous treatment, comparing them to standard chemotherapy. It aims to see which treatment works best.
Australia · Hong Kong · Japan - active not recruitingPHASE1, PHASE2
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
This study is testing a new drug, E7386, alongside other cancer medicines. It aims to find the safest and most effective dose for people with various solid tumours, especially endometrial cancer, and to understand how these combinations work.
United States · Canada · China - active not recruitingPHASE3
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
This study is looking into new ways to treat advanced or recurrent womb cancer. We're testing a combination of medicines called durvalumab and olaparib, given after initial chemotherapy, to see if they can help patients live longer and better.
United States · Australia · Belgium - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This study is testing a cancer drug called atezolizumab in people with certain cancers that have specific genetic changes. Atezolizumab is already used for some cancers, and this study wants to see if it can help other types of cancer that share these same genetic features.
United Kingdom - active not recruitingPHASE2
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
This study is testing a new drug, disitamab vedotin, for certain advanced cancers like head and neck, lung, ovarian, and endometrial cancer. It's for people whose cancer has a marker called HER2 and has already been treated. The study wants to see how well the new drug works and if it's safe.
United States · Australia · Canada - authorisedHuman Pharmacology (Phase I)- First administration to humans
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
This study is testing a new medicine called LY4257496 for people with certain types of cancer, including breast, bowel, prostate, and womb cancer, especially if it has spread. It's the first time this medicine is being given to people, to check if it's safe and how it works in the body.
Germany - active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
This study is looking at a new treatment called pembrolizumab for advanced or recurrent womb cancer that has a specific genetic marker. It compares this new treatment to standard chemotherapy to see which works better and is safer for women who haven't had chemotherapy for this stage of cancer before.
United States · Australia · Belgium